Table 1.

Clinical characteristics in the four subtypes

Variable	All tumors	TC	AC	LCNEC	SCLC	NA
	159 (100.0)	35 (100.0)	2 (100.0)	28 (100.0)	94 (100.0)
Age
< =59.5	78 (49.1)	25 (71.4)	2 (100.0)	12 (42.9)	39 (41.5)
> 59.5	81 (50.9)	10 (28.6)	0 (0.0)	16 (57.1)	55 (58.5)
Gender
Male	109 (68.6)	17 (48.6)	0 (0.0)	23 (82.1)	69 (73.4)
Female	50 (31.4)	18 (51.4)	2 (100.0)	5 (17.9)	25 (27.6)
Necrosis
No	85 (53.5)	35 (100.0)	0 (0.0)	9 (32.1)	41 (43.6)
Yes	74 (46.5)	0 (0.0)	2 (100.0)	19 (67.9)	53 (56.4)
Vascular invasion
No	129 (81.1)	34 (97.1)	1 (50.0)	22 (78.6)	72 (76.6)
Yes	30 (18.9)	1 (2.9)	1 (50.0)	6 (21.4)	22 (23.4)
Preoperative therapy
No	150 (94.3)	35 (100.0)	2 (100.0)	27 (96.4)	86 (91.5)
Yes	9 (5.7)	0 (0.0)	0 (0.0)	1 (3.6)	8 (8.5)
First location
Lung	131 (82.4)	35 (100.0)	2 (100.0)	28 (100.0)	66 (70.2)
Lymph Node	28 (17.6)	0 (0.0)	0 (0.0)	0 (0.0)	28 (29.8)
Lymph Node Metastasis						13 (8.2)
No	83 (52.2)	32 (97.0)	1 (50.0)	14 (60.9)	36 (40.9)
Yes	63 (47.8)	1 (3.0)	1 (50.0)	9 (39.1)	52 (59.1)
Clinical Staging						15 (9.4)
I	70 (48.6)	30 (90.9)	1 (50.0)	10 (43.5)	29 (33.7)
II	27 (18.8)	2 (6.1)	0 (0.0)	9 (39.1)	16 (18.6)
III	47 (32.6)	1 (3.0)	1 (50.0)	4 (17.4)	41 (47.7)
Patterns of PD-L1
Tumorpos stromaneg	9 (5.7)	3 (8.6)	0 (0.0)	5 (17.8)	1 (1.1)
Stromapostumorneg	46 (28.9)	0 (0.0)	0 (0.0)	12 (42.9)	34 (36.2)
Tumor and stromapos	17 (10.7)	0 (0.0)	0 (0.0)	4 (14.3)	13 (13.8)
Tumor and stromaneg	87 (54.7)	32 (91.4)	2 (100.0)	7 (25.0)	46 (48.9)
CD8 density/mm2 in stroma
≤ 264.6/mm2	80 (50.3)	23 (65.7)	0 (0.0)	7 (25.0)	50 (53.2)
> 264.6/mm2	79 (49.7)	12 (34.3)	2 (100.0)	21 (75.0)	44 (46.8)

Abbreviation: NA not available